Skip to Content

Global X China Biotech Innovation ETF CHB

Medalist Rating as of | See Global X Investment Hub

Morningstar’s Analysis CHB

Will CHB outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Global X China Biotech Innovation ETF’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research


The portfolio maintains a cost advantage over competitors, priced within the cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CHB

  • Current Portfolio Date
  • Equity Holdings 40
  • Bond Holdings 0
  • Other Holdings 2
  • % Assets in Top 10 Holdings 61.5